.

Intended Audience
This complimentary CME educational activity is designed for cardiologists, endocrinologists, diabetes specialists, internists, primary care physicians and other healthcare professionals who treat patients with diabetes.

Program Medium
Internet-based program

Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period February 14, 2013 through February 14, 2015 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 107 segments totaling 4 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate

Estimated Time to Complete Educational Activity
4.0 hours

Course Overview
In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of advances in cardiovascular risk reduction in the setting of diabetes.

Release Date
February 14, 2013

Expiration Date
February 14, 2015

Registration
Participation in this iQ&A interactive Medical Intelligence Zone for Cardiometabolic Risk Reduction in the Type 2 Diabetes and ACS is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support
Supported by an educational grant from Roche.
Roche

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
The University of Massachusetts Medical School designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Program Chair
A. MICHAEL LINCOFF, MD 

Vice Chairman
Department of Cardiovascular Medicine
Cleveland Clinic
Professor of Medicine 
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio

Consultant: AstraZeneca, Avanir, Edwards Lifesciences, Ikaria (Data Safety Monitoring Committee), Roche, Merck/Schering-Plough
Research Funding: Aastrom, Anthera, AstraZeneca, BMS, Cardiovascular Systems, Centocor, Edwards Lifesciences, Eli Lilly (Principal Investigator), Ethicon, J & J, Juventas, Kai Pharmaceutical (Principal Investigator), Karo Bio, Medtronic, Merck/Schering-Plough (National Coordinator), Novartis, Orexigen, Pfizer (Co-Principal Investigator), Regado, Reserverlogix, Roche (Principal Investigator), Sanofi-aventis, Scios, Takeda (Principal Investigator), VIVUS (Principal Investigator)

 

CHRISTIE M. BALLANTYNE, MD
Director, Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart Center
Chief of the Section of Cardiovascular Research
Baylor College of Medicine
Director of Atherosclerosis Laboratory
Professor of Medicine
Baylor College of Medicine
Houston, TX

Advisor or Consultant: Abbott Laboratories; Amarin Corporation plc; Adnexus; Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Esperion Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Idera Pharmaceuticals Inc.; Kowa Company Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Omthera Pharmaceuticals, Inc.; Resverlogix Corp; Roche; sanofi-aventis; Synthelabo; Takeda Pharmaceuticals North America, Inc.
Speaker or Speakers Bureau: Abbott Laboratories; GlaxoSmithKline; Merck & Co., Inc.

 

RICHARD C. BECKER, MD
Professor of Medicine 
School of Medicine
Duke University
Director, Duke Cardiovascular Thrombosis Center
Duke Clinical Research Institute
Durham, North Carolina

Grant/Research Support: Johnson & Johnson, Bristol-Myers Squibb, Bayer, Merck, Regado Biosciences

 

DEEPAK L. BHATT, MD, MPH, FACC, FAHA, FSCAI 
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular
Program, Brigham and Women’s Hospital and the
VA Boston Healthcare System
Senior Investigator, TIMI Group
Harvard Medical School
Boston, Massachusetts

Consultant: Arena, Astra Zeneca, Bristol-Myers Squibb, Cardax, Cogentus, Daiichi Sankyo, Eli Lilly, Eisai, Glaxo Smith Kline, Johnson & Johnson, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, sanofi-aventis, Schering Plough, Takeda, The Medicines Company, Vertex.
Principal Investigator for several potentially related studies. His institution has received funding from Bristol Myers Squibb, Eisai, Ethicon, Heartscape, sanofi-aventis, The Medicines Company

 

RAFAEL CARMENA, M.D, PhD, FACP, FRCP Edin
Professor of Internal Medicine and Endocrinology
University of Valencia
Chief of the Endocrine and Nutrition Service
University Hospital
Valencia, Spain

Nothing to disclose

 

MATTHEW A. CAVENDER, MD
Research Fellow, TIMI Study Group
Brigham and Women's Hospital 
Harvard Medical School
Boston, MA

Nothing to disclose

 

ROBERT J. CHILTON, DO, FACC
Associate Professor
Department of Medicine, Division of Cardiology
The University of Texas Health Science Center at San Antonio
San Antonio, Texas

Advisory Board: Pfizer, Bristol-Myers Squibb, Eli Lilly

 

ROBIN CHOUDHURY, MD
Distinguished Program Chairman
Wellcome Trust Senior Research Fellow, Clinical Science
University of Oxford
Consultant Cardiologist, John Radcliffe Hospital
Clinical Director, Oxford Acute Vascular Imaging Centre
Oxford, England

Consultant: Roche, sanofi-aventis, AstraZeneca
Speaker: Merck
Research Support: Merck, Novartis

 

MICHAEL DAVIDSON, MD
Clinical Professor
The University of Chicago Pritzker School of Medicine
Director of Preventive Cardiology
The University of Chicago Pritzker School of Medicine
Chicago, Illinois

Advisory Board/Consultant: Amgen, Merck, Roche, Sanofi-aventis
Stockholder: Omthera Pharmaceuticals

 

PROFESSOR JOHN E. DEANFIELD BA Hons (Cantab) BChir MB FRCP FRCP
BHF Vandervell Chair of Congenital Heart Disease
Director Centre for Cardiovascular Prevention & Outcomes
Deputy Cardiovascular Program Director, UCL Partners
University College of London
School of Life and Medical Sciences
London, United Kingdom

Nothing to disclose

 

DARREN K. McGUIRE, MD, MHSc, FAHA, FACC
Associate Professor of Medicine
Associate of the Donald W. Reynolds Cardiovascular Clinical Research Center
Director, Parkland Hospital and Health System Outpatient Cardiology Clinics
University of Texas Southwestern Medical Center
Dallas, TX

Consultant: Boehringer-Ingelheim, Daiichi-Sankyo, Janssen, Genentech, Roche
Honorariua: Boehringer-Ingelheim, Daiichi-Sankyo, Janssen, Genentech, Roche

 

GILLES MONTALESCOT, MD, PhD
Professor of Cardiology
Institut de Cardiologie
Hôpital la Pitie-Salpêtrière
Paris, France

Consultant: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eli Lilly and Company; GlaxoSmithKline; Menarini Group; Nanosphere, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Portola Pharmaceuticals, Inc.; sanofi-aventis; The Medicines Company
Research Support: Received grants for clinical research from: Abbott Laboratories; AstraZeneca Pharmaceuticals; Boston Scientific; Bristol-Myers Squibb Company; Cordis Corporation; Eli Lilly and Company; Guerbet; ITC, Edison, NJ; Medtronic, Inc.; Pfizer; sanofi-aventis; SERVIER; Stago

 

JORGE PLUTZKY, MD
Director, The Vascular Disease Prevention Program Cardiovascular Division
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consultant: Abbott, Amylin Pharmaceuticals, BMS, Daiichi Sankyo, GSK, Merck, Novo Nordisk, Orexigen, Pfizer, Roche/Genentech, Takeda, Vivus

 

PAUL RIDKER, MD
Eugene Braunwald Professor of Medicine
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

Research Grant: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation;
Amgen Inc
Consultant/Advisory Board: Merck & Co., Inc.; Isis Pharmaceuticals, Inc.; Vascular Biogenics Ltd.; Amylin
Pharmaceuticals, Inc.; Genzyme Corporation

 

LUIS M. RUILOPE, MD
Associate Professor of Internal Medicine
Complutense University of Madrid
Head, Hypertension Unit
Hospital Octubre
Madrid, Spain

Executive Committee ALePrevent Study: Roche

 

PHILIPPE GABRIEL STEG, MD, FESC, FACC
Director, Coronary Care Unit
Hôpital Bichat-Claude Bernard
Professor of Cardiology
University Paris VII 
Paris, France

Consultant: Eisai, GlaxoSmithKline, Otsuka, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol–Myers Squibb, Daiichi Sankyo, Medtronic, Merck Sharp & Dohme, Novartis
Speaker’s Bureau: The Medicines Company
Grant/Research Support: SERVIER, Sanofi
Shareholder: Aterovax

 

PETER P. TOTH, MD, PhD
Director of Preventative Cardiology
CGH Medical Center
Sterling, Illinois
Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine
Peoria, Illinois

 

JAMES A. UNDERBERG, MD, MS, FACPM, FACP, FASH, FNLA
Preventive CV Medicine, Lipidology and Hypertension
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY

Speaker: Honoraria

 

R. SCOTT WRIGHT, MD
Consultant, Cardiovascular Diseases
Professor of Medicine
College of Medicine
The Mayo Clinic
Rochester, Minnesota

Consultant: Roche, 3-M, Phillips, American College of Cardiology, American Academy of Sleep Medicine

 


Program Managers and Web Editor Disclosure
Program Manager Gideon Bosker, MD has nothing to disclose.
Program Reviewer Denise Leary has nothing to disclose.



Educational Objectives
Upon completion of this activity, participants will be able to:



Disclaimer

Copyright © 2013 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations. 

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman. 

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC

Click here to indicate that you have read this CME information statement and wish to participate in this CME activity.

iQ&A Interactive Medical Intelligence Zone for PPARs & CV RISK REDUCTION IN T2D